Status:
COMPLETED
Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study
Lead Sponsor:
University of Michigan
Conditions:
Chronic Kidney Disease
Anemia
Eligibility:
All Genders
18+ years
Brief Summary
Humans have cells in their blood stream called endothelial progenitor cells or EPCs. These are thought to be important in keeping blood vessels healthy. People with chronic kidney disease (CKD) have l...
Detailed Description
The majority of patients with kidney disease, an estimated 20 million adults in the U.S., will die of cardiovascular disease. Further, the risk for cardiovascular events is 2-3 fold higher than in the...
Eligibility Criteria
Inclusion
- Enrolled in University of Michigan's Nephrology Anemia Clinic
- 18 years old or older
- Have kidney disease but are not on dialysis
Exclusion
- Not enrolled in University of Michigan's Nephrology Anemia Clinic
- Less than 18 years of age
- Hematocrit that is less than 28.5%
- Currently participating in a clinical trial with an intervention
- Planning to change their tobacco use habits during the study period
- Have had dose changes of certain medications for cholesterol or diabetes within one month of study enrollment
- Are currently receiving:
- darbepoetin
- erythopoietin
- medications to lower your immune system
- Have had problems within the last 3 months with:
- Bleeding
- Heart attack or stroke
- Heart or blood vessel procedures
- Are pregnant or lactating
Key Trial Info
Start Date :
November 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 25 2008
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00396123
Start Date
November 1 2006
End Date
July 25 2008
Last Update
June 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109